Concurrent ezetimibe with maximally tolerated statin — ACC/AHA · 2025 recommendation
2025 ACC/AHA acute coronary syndromes guideline
For ACS, concurrent initiation of ezetimibe with maximally tolerated statin therapy may be considered to reduce major adverse cardiovascular events.
Class of Recommendation
Class 2b
Level of Evidence
Level B-R
Last source-check date
2026-08-23
Exact source location
Section 4.5, ‘Recommendations for Lipid Management’, recommendation 5, p. e797
Prepared source-record governance
This record is prepared from a stored source. It is not labelled reviewer-verified because named reviewer provenance has not been documented.
- Clinical reviewer
- Not yet documented.
- Reviewer credentials
- Not yet documented.
- Last source-check date
- 2026-08-23
- Second-review status
- Not yet documented.
- Conflict-of-interest declaration
- Not yet documented.
- Source publication date
- Not yet documented.
- Source access date
- Not yet documented.
- Record version
- Not yet documented.
- Change history
- Not yet documented.
- Next review date
- Not yet documented.
Verification status & editorial record
Status: Prepared source record — reviewer provenance not documented.
Last source-check: 2026-08-23
No formally approved public metadata is currently available for a named reviewer, second-review status, conflict declaration, publication or access date, version history, or next review date for this record.
Verification boundary: This concise reference is limited to a prepared source recommendation. Verify the official document, local protocol, and patient context before application.